This article is more than 5 years old. Information may no longer be current.

InSite initiates phase 1 study of antibiotic-steroid combination drug

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ALAMEDA, Calif. — InSite Vision Inc. has begun a phase 1 study of its combination antibiotic/corticosteroid AzaSite Plus, the company announced in a press release.

The Food and Drug Administration accepted a new drug application for AzaSite for treating bacterial conjunctivitis in August 2006. The new formulation combines azithromycin and dexamethasone for treating conditions involving both ocular inflammation and bacterial infection, such as blepharitis, according to the release.

The phase 1 trial will evaluate the safety and tolerability of the AzaSite Plus formulation in normal volunteers, according to the release.